SVRA — Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 59
- Website: https://www.savarapharma.com
Latest SEC filings for SVRA
- 10-Q — 2026-08-11
- S-8 — 2026-08-11
- ARS — 2026-04-24
- 10-Q — 2025-11-12
- 8-K — 2025-10-30
- 424B5 — 2025-10-30
- 8-K — 2025-10-29
- 424B5 — 2025-10-29
- 8-K — 2025-09-02
- 10-Q — 2025-08-13
Latest SVRA news
- — Bybit ottiene una licenza VARA per i servizi di cambio a Dubai (prnewswire_all)
- — Bybit obtient une licence VARA pour ses services de plateforme d'échange à Dubaï (prnewswire_all)
- — Bybit Secures VARA Licence for Exchange Services in Dubai (prnewswire_financial)
- — Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026 (businesswire.com)
- — Caladan Receives In-Principle Approval from VARA (prnewswire_financial)
Educational tool only — not investment advice.